Navigation Links
UTMB receives $3.2 million to continue collaborative research on cancer in Texas
Date:3/7/2014

The Cancer Prevention and Research Institute of Texas has awarded the University of Texas Medical Branch at Galveston more than $3.2 million to continue a program aimed at creating a new state resource a trove of population research on cancer treatments and outcomes in Texas.

One of 11 multi-investigator research continuation grants recently announced by CPRIT, the UTMB award will fund the work of the organization Comparative Effectiveness Research on Cancer in Texas for two more years.

Led by Dr. James Goodwin, vice president and chief research officer at UTMB, CERCIT is a multidisciplinary consortium of investigators from UTMB, the University of Texas MD Anderson Cancer Center, Rice University and the Texas Cancer Registry.

CERCIT researchers are studying how screening for breast, colon and prostate cancer is conducted throughout the state. They are looking at how access to care and quality of cancer care affect patient outcomes. They are investigating how long health care providers carry out surveillance of cancer survivors.

"This has been a very rich collaboration. The investigators from these institutions work well together," said Goodwin. "Our different disciplines and skill sets create great synergy, not only in research, but also in training the next generation of cancer investigators."

CERCIT was originally funded by CPRIT in 2010. Since then, the organization has become a major presence in Texas's cancer research community.

One of its research projects culminated in the development of a white paper on cancer statistics among Hispanics in Texas distributed to 1,000 legislators and influential individuals and organizations in the Hispanic community nationwide. This is the first time any such research had ever been compiled and disseminated.

Over the course of its first four years, CERCIT has trained 24 new cancer researchers and published more than 80 peer-reviewed cancer studies in such high-profile journals as the Journal of the American Medical Association and the New England Journal of Medicine. To learn more, visit the CERCIT website at http://www.txcercit.org.

Founded in 2009, CPRIT has to date awarded more than $850 million in grants to Texas researchers, institutions, non-profits and private enterprises. Besides funding scientific cancer research, CPRIT also funds product development and prevention programs. Programs made possible with CPRIT funding have reached every corner of the state, brought more than 50 distinguished researchers to Texas, advanced scientific and clinical knowledge, and made life-saving education, training, prevention and early detection services accessible to more than 1.3 million Texans at risk of cancer. In 2013, CPRIT worked with the Texas Legislature and its stakeholders on restructuring measures that have strengthened agency governance and improved transparency and accountability.


'/>"/>

Contact: Molly Dannenmaier
mjdannen@utmb.edu
409-771-5105
University of Texas Medical Branch at Galveston
Source:Eurekalert

Related medicine news :

1. Loyola Cancer Center receives Outstanding Achievement Award
2. MU receives national award for using mind-body approach to improve health
3. Neuropsychologist receives University of Houstons highest faculty honor
4. Boston researcher, surgical oncologist receives national award
5. LA BioMed receives Grand Challenges Explorations grant
6. Lawson researcher receives 1 of first-ever Pfizer Psychiatry Research Awards
7. Dr. Arthur Slutsky, vice-president of research at St. Michaels, receives lifetime award
8. UC San Diego Superfund Research Program receives $15 million grant renewal
9. Markey receives $6.25 million to study deadly blood and bone marrow disease
10. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
11. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... March 01, 2017 , ... ... permanently embedded anti-odor solution to cotton knit and woven fabrics. , Retail ... maintaining the luxurious look and feel of cotton. Cotton Incorporated has developed ...
(Date:3/1/2017)... HILLS, CA (PRWEB) , ... March 01, 2017 , ... ... cryoablation for the treatment of early stage breast cancer and where it fits in ... Genes & The Choices We Make .” The event brings together leading cancer and ...
(Date:3/1/2017)... ... March 01, 2017 , ... Expert on international living and leading a ... & Go. , Time & Go app is the ultimate strategic compass that helps ... time management methods enable people to work smarter, not harder, that's why Time & ...
(Date:3/1/2017)... York, NY & Greenwich, CT (PRWEB) , ... March 01, 2017 ... ... many runners, especially in the winter months when people don’t want to stop training ... the knees – and setting the treadmill to a small incline can help protect ...
(Date:3/1/2017)... ... March 01, 2017 , ... “McFarnia”: a suspenseful tale of ... truth about his life and mysterious disappearance. “McFarnia” is the creation of published author ... North Carolina. He currently serves as a Chaplain with Transport for Christ at a ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Calif. , March 1, 2017   Sun Chlorella ... about all things chlorella, is pleased to announce Non-GMO Project ... premium chlorella powder. Just in time for the ... in Anaheim, CA , Sun Chlorella Corp. ... all chlorella products, including: Sun Chlorella ...
(Date:3/1/2017)... 2017  Integrated Modular Design (IMD), a ... implementation of pre-fabricated healthcare products like bathroom ... seeks to lead the construction industry toward ... Fueled by their leading-edge pre-fabrication solutions, ... construction timelines and project risk, and increasing ...
(Date:3/1/2017)... 1, 2017  Global biotherapeutics leader CSL Behring ... ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as ... reatment with H izentra ® ).  The Phase ... safety and tolerability of two different doses of CSL ... Subcutaneous [Human]), compared with placebo, in the maintenance treatment ...
Breaking Medicine Technology: